drugset / Trial / NCT06177301
Tislelizumab Plus GX Versus Tislelizumab Plus GP in the Treatment of R/M NPC
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The study is being conducted to evaluate the safety and efficacy of tislelizumab combined with GX regimen versus tislelizumab combined with GP regimen in the first-line treatment of nasopharyngeal carcinoma.
Timeline
- Start
- 2023-12-01
- Primary completion
- 2026-12
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 1000 mg/m2 | Oral |
| Subject | Cisplatin | Other / unclassified | 80 mg/m2 | Intravenous |
| Background | Gemcitabine | Small molecule | 1000 mg/m2 | Other |
| Background | Tislelizumab | Monoclonal antibody | 200 mg | Other |